Sunday, September 13, 2026
ExploreSearch
Finance Via News

Corporate Valuation

2 articles

10-Year Treasury Yield Climbing Toward 5% Splits AI Sector Into Valuation Winners and Losers

10-Year Treasury Yield Climbing Toward 5% Splits AI Sector Into Valuation Winners and Losers

The 10-Year US Treasury yield has moved from 4.58 toward 5.0, raising discount rates across equity markets. Unprofitable AI infrastructure firms face the steepest valuation pressure, while profitable AI enterprise software companies with near-term cash flows remain more insulated. Global rate pressure is compounding the effect, with Japanese 10-Year bond yields jumping from 2.478 to 2.807.

LM Salvado•
Tesla Valuation Driven by AI Narrative Over EV Fundamentals, Analysts Say

Tesla Valuation Driven by AI Narrative Over EV Fundamentals, Analysts Say

Tesla's stock pricing reflects investor focus on AI optionality—autonomous driving, robotics, energy software—rather than core electric vehicle sales. UBS recently upgraded Tesla after raising its price target, citing long-term opportunities balancing near-term EV demand challenges. Analyst Joseph Spak notes the stock trades on sentiment and momentum, creating persistent volatility and divergence between traditional auto analysts and tech-focused investors.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com